» Articles » PMID: 38153923

Cluster-based Prognostication in Glioblastoma: Unveiling Heterogeneity Based on Diffusion and Perfusion Similarities

Overview
Journal Neuro Oncol
Specialties Neurology
Oncology
Date 2023 Dec 28
PMID 38153923
Authors
Affiliations
Soon will be listed here.
Abstract

Background: While the association between diffusion and perfusion magnetic resonance imaging (MRI) and survival in glioblastoma is established, prognostic models for patients are lacking. This study employed clustering of functional imaging to identify distinct functional phenotypes in untreated glioblastomas, assessing their prognostic significance for overall survival.

Methods: A total of 289 patients with glioblastoma who underwent preoperative multimodal MR imaging were included. Mean values of apparent diffusion coefficient normalized relative cerebral blood volume and relative cerebral blood flow were calculated for different tumor compartments and the entire tumor. Distinct imaging patterns were identified using partition around medoids (PAM) clustering on the training dataset, and their ability to predict overall survival was assessed. Additionally, tree-based machine-learning models were trained to ascertain the significance of features pertaining to cluster membership.

Results: Using the training dataset (231/289) we identified 2 stable imaging phenotypes through PAM clustering with significantly different overall survival (OS). Validation in an independent test set revealed a high-risk group with a median OS of 10.2 months and a low-risk group with a median OS of 26.6 months (P = 0.012). Patients in the low-risk cluster had high diffusion and low perfusion values throughout, while the high-risk cluster displayed the reverse pattern. Including cluster membership in all multivariate Cox regression analyses improved performance (P ≤ 0.004 each).

Conclusions: Our research demonstrates that data-driven clustering can identify clinically relevant, distinct imaging phenotypes, highlighting the potential role of diffusion, and perfusion MRI in predicting survival rates of glioblastoma patients.

Citing Articles

Shape matters: unsupervised exploration of IDH-wildtype glioma imaging survival predictors.

Foltyn-Dumitru M, Mahmutoglu M, Brugnara G, Kessler T, Sahm F, Wick W Eur Radiol. 2024; 35(3):1351-1360.

PMID: 39251442 PMC: 11835892. DOI: 10.1007/s00330-024-11042-6.

References
1.
Ellingson B, Bendszus M, Boxerman J, Barboriak D, Erickson B, Smits M . Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015; 17(9):1188-98. PMC: 4588759. DOI: 10.1093/neuonc/nov095. View

2.
Aquilanti E, Miller J, Santagata S, Cahill D, Brastianos P . Updates in prognostic markers for gliomas. Neuro Oncol. 2018; 20(suppl_7):vii17-vii26. PMC: 6225747. DOI: 10.1093/neuonc/noy158. View

3.
Ostergaard L, Weisskoff R, Chesler D, Gyldensted C, Rosen B . High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med. 1996; 36(5):715-25. DOI: 10.1002/mrm.1910360510. View

4.
van Dijken B, van Laar P, Smits M, Dankbaar J, Enting R, van der Hoorn A . Perfusion MRI in treatment evaluation of glioblastomas: Clinical relevance of current and future techniques. J Magn Reson Imaging. 2018; 49(1):11-22. PMC: 6590309. DOI: 10.1002/jmri.26306. View

5.
Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View